Category Archives: Patently BIOtech

Special 301: BIO Highlights Challenges in India

cells115x76

BIO recently testified before the U.S. government on the intellectual property challenges our members face in various markets around the world. Among other matters, BIO recommended that the U.S. government designate India as a Priority Foreign Country, a designation that would lead to the consideration of trade sanctions for treaty violations. Specifically, BIO testified: “In the healthcare space, only a few dozen innovative and patent protected medicines are on the market in India. Yet, in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Report Shows World’s Weakest IP Environments

admin-ajax

There is clear link between a country’s rate of economic development and the strength of its intellectual property laws. This is particularly true in knowledge-intensive sectors such as biopharmaceuticals. The good news is that some mature and emerging economies are making growing use of patent systems to facilitate biotechnology research and commercialization. The bad news is that a number of countries, including India, China, Brazil and Canada, have established bureaucratic and burdensome hurdles to patentability. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

TPP and IP: The Economic Benefits of a Pacific Trade Agreement

scientists115x76

Ndp Analytics recently published a study on the economic benefits of intellectual property rights (IP) in the Trans-Pacific Partnership. They find that 2/3’s of the “economic benefits for the U.S. economy and the 11 partner countries would come from IP-intensive manufacturing industries.” They conclude that “the stronger the protection of IP rights under the TPP, the greater the value of trade leading to greater economic growth, additional jobs created, higher incomes, and development across countries.” Here Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Patently Biotech’s Top Articles of 2013

lab_tech02-thumb

Intellectual property featured prominently in 2013’s public discourse. Gene patents, patent trolls, India’s anti-patent actions, and other developments around the world captured headlines. Here are Patently Biotech’s top blog posts written in 2013 by number of views. 1.   Myriad Supreme Court Decision: BIO’s Statement 2.  Kirtsaeng v. John Wiley & Sons: No Good Deed Goes Unpunished 3.  What a Patent is Not 4.  Gene Patents, Angelina Jolie, and Reality 5.  What OxyContin Tells Us About Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Universities Express Concerns About Recently Passed House “Innovation Act”

Earlier this month, the House passed the Innovation Act (H.R. 3309), which seeks to address abuses of the U.S. patent litigation system. While the goal is commendable, the bill is overly broad in important respects and if enacted into law would produce unintended and unknowable consequences for innovators who rely on the patent system to fund and protect their inventions. The U.S. Senate is now developing similar legislation, the Patent Transparency and Improvement Act of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,